How to buy Exicure stock | $1.18

Exicure Inc is a biotechnology business based in the US. Exicure shares (XCUR) are listed on the NASDAQ and all prices are listed in US Dollars. Exicure employs 78 staff and has a trailing 12-month revenue of around 0.00.

Exicure stock price (NASDAQ: XCUR)

Use our graph to track the performance of XCUR stocks over time.

Exicure shares at a glance

• Key figures

Information last updated 2021-10-10.

Latest market close	$1.18
52-week range	$1.09 - $2.83
50-day moving average	$1.31
200-day moving average	$1.56
Wall St. target price	$6.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.55

Buy Exicure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Exicure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exicure price performance over time

Historical closes compared with the close of $1.18 from 2021-10-15

1 week (2021-10-08)	-7.81%
1 month (2021-09-17)	-16.31%
3 months (2021-07-17)	-24.36%
6 months (2021-04-16)	-34.44%

1 year (2020-10-16)	-40.40%
2 years (2019-10-16)	-57.71%
3 years (2018-10-16)	4.42
5 years (2016-10-13)	N/A

Exicure financials

Revenue TTM	$3.7 million
Gross profit TTM	$-15,481,000
Return on assets TTM	-34.88%
Return on equity TTM	-81.51%
Profit margin	0%
Book value	$0.42
Market capitalisation	$112.8 million

TTM: trailing 12 months

Shorting Exicure shares

There are currently 2.5 million Exicure shares held short by investors – that's known as Exicure's "short interest". This figure is 13.7% down from 2.9 million last month.

There are a few different ways that this level of interest in shorting Exicure shares can be evaluated.

Exicure's "short interest ratio" (SIR)

Exicure's "short interest ratio" (SIR) is the quantity of Exicure shares currently shorted divided by the average quantity of Exicure shares traded daily (recently around 393739.78328173). Exicure's SIR currently stands at 6.46. In other words for every 100,000 Exicure shares traded daily on the market, roughly 6460 shares are currently held short.

However Exicure's short interest can also be evaluated against the total number of Exicure shares, or, against the total number of tradable Exicure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exicure's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Exicure shares in existence, roughly 30 shares are currently held short) or 0.0425% of the tradable shares (for every 100,000 tradable Exicure shares, roughly 43 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Exicure.

Find out more about how you can short Exicure stock.

Exicure share dividends

We're not expecting Exicure to pay a dividend over the next 12 months.

Exicure share price volatility

Over the last 12 months, Exicure's shares have ranged in value from as little as $1.09 up to $2.83. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exicure's is 1.3402. This would suggest that Exicure's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Exicure overview

Exicure, Inc. , a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S. A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.

Frequently asked questions

What percentage of Exicure is owned by insiders or institutions?
Currently 23.571% of Exicure shares are held by insiders and 35.212% by institutions. How many people work for Exicure?
Latest data suggests 78 work at Exicure. When does the fiscal year end for Exicure?
Exicure's fiscal year ends in December. Where is Exicure based?
Exicure's address is: 2430 North Halsted Street, Chicago, IL, United States, 60614 What is Exicure's ISIN number?
Exicure's international securities identification number is: US30205M1018 What is Exicure's CUSIP number?
Exicure's Committee on Uniform Securities Identification Procedures number is: 30205M101